These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 17062041)
1. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. Körver JE; Langewouters AM; Van De Kerkhof PC; Pasch MC J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1252-5. PubMed ID: 17062041 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184 [TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328 [TBL] [Abstract][Full Text] [Related]
5. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207 [TBL] [Abstract][Full Text] [Related]
6. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y; Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389 [TBL] [Abstract][Full Text] [Related]
7. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment. Rigopoulos D; Gregoriou S; Daniel Iii CR; Belyayeva H; Larios G; Verra P; Stamou C; Kontochristopoulos G; Avgerinou G; Katsambas A Dermatology; 2009; 218(4):338-41. PubMed ID: 19212110 [TBL] [Abstract][Full Text] [Related]
8. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis. Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631 [TBL] [Abstract][Full Text] [Related]
9. Nail psoriasis successfully treated with intralesional methotrexate: case report. Sarıcaoglu H; Oz A; Turan H Dermatology; 2011 Feb; 222(1):5-7. PubMed ID: 21228554 [TBL] [Abstract][Full Text] [Related]
10. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563 [TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270 [TBL] [Abstract][Full Text] [Related]
12. The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis. Langewouters AM; Van Erp PE; De Jong EM; Van De Kerkhof PC J Dermatolog Treat; 2006; 17(6):362-9. PubMed ID: 17853311 [TBL] [Abstract][Full Text] [Related]
13. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. Ortonne JP; Khemis A; Koo JY; Choi J J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708 [TBL] [Abstract][Full Text] [Related]
14. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Legat FJ; Hofer A; Wackernagel A; Salmhofer W; Quehenberger F; Kerl H; Wolf P Arch Dermatol; 2007 Aug; 143(8):1016-22. PubMed ID: 17709660 [TBL] [Abstract][Full Text] [Related]
15. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. Parrish CA; Sobera JO; Robbins CM; Cantrell WC; Desmond RA; Elewski BE J Drugs Dermatol; 2006 Apr; 5(4):339-40. PubMed ID: 16673801 [TBL] [Abstract][Full Text] [Related]
16. [Assessment of psoriatic nail lesions therapy by means of nail psoriasis severity index]. Tsiskarishvili NV; Katsitadze AG; Tsiskarishvili NI Georgian Med News; 2011 Oct; (199):43-7. PubMed ID: 22155805 [TBL] [Abstract][Full Text] [Related]
17. Remittive effects of intramuscular alefacept in psoriasis. Gordon KB; Langley RG J Drugs Dermatol; 2003 Dec; 2(6):624-8. PubMed ID: 14711140 [TBL] [Abstract][Full Text] [Related]
18. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E; J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Rigopoulos D; Gregoriou S; Makris M; Ioannides D Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046 [TBL] [Abstract][Full Text] [Related]
20. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response. Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]